<DOC>
	<DOCNO>NCT00783341</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics ( PK ) ascend dos GAP 134 administer 6-day continuous IV infusion healthy subject .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics GAP-134 Administered Intravenously</brief_title>
	<detailed_description />
	<criteria>Inclusion 1 . Men woman non childbearing potential ( WONCBP ) age 18 50 year inclusive screening . 2 . Body mass index ( BMI ) range 18.0 30.0 kg/m2 body weight â‰¥50 kg . 3 . Healthy determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign measurement , 12lead electrocardiogram ( ECG ) . 4 . Serum creatinine level must less 1.30 mg/dL . ( Normal range : 0.44 1.24 mg/dL . ) 5 . Nonsmoker smoker few 10 cigarette per day determine history . Must able abstain smoking inpatient stay . Exclusion 1 . Presence history disorder may prevent successful completion study . 2 . Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . 3 . Any surgical medical condition may interfere distribution , metabolism , excretion test article . 4 . Acute disease state ( eg , nausea , vomit , fever , diarrhea ) within 7 day study day 1 . 5 . Any history clinically important cardiac arrhythmia . 6 . Familial history long QT syndrome unexpected cardiac death . 7 . History drug abuse within 1 year study day 1 . 8 . History alcoholism within 1 year study day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>